migaldendranib

Migaldendranib is a novel, first-in-class subcutaneously administered nanomedicine developed for the treatment of retinal vascular diseases, specifically wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). It is a VEGF receptor tyrosine kinase inhibitor covalently linked to a hydroxyl dendrimer platform. This design enables selective targeting and uptake by activated cells in the retina—such as retinal pigment epithelial cells, macrophages, and microglia—in regions of inflammation. Migaldendranib reduces VEGF expression and fluid production in both eyes simultaneously with monthly at-home subcutaneous dosing. The drug demonstrates an excellent safety profile with minimal systemic side effects due to its specificity and rapid renal clearance; it is retained in target cells for about 30 days but cleared from the body within two days. Clinical studies have shown that migaldendranib significantly reduces the need for intravitreal anti-VEGF injections while maintaining or improving visual acuity and central subfield thickness[1][2][3][4][6][8].

Other names

hydroxyl dendrimer VEGFR tyrosine kinase inhibitorHDT (hydroxyl dendrimer therapeutic)